<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692065</url>
  </required_header>
  <id_info>
    <org_study_id>P170604J</org_study_id>
    <nct_id>NCT03692065</nct_id>
  </id_info>
  <brief_title>API-CAT STUDY for APIxaban Cancer Associated Thrombosis</brief_title>
  <acronym>API-CAT</acronym>
  <official_title>Long-term Treatment of Cancer Associated VTE: Reduced vs Full Dose of Apixaban : API-CAT STUDY for APIxaban Cancer Associated Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non
      inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous
      thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of
      anticoagulant therapy for treating a documented index event of proximal deep venous
      thrombosis (DVT) (symptomatic or incidental) or pulmonary embolism (symptomatic or
      incidental).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients completing at least 6 months of anticoagulant therapy in whom the cancer is
      active, the thrombotic risk is arguably ongoing and indefinite anticoagulation seems
      required.

      Given apixaban 5 mg bid is an alternative for the first 6 months of treatment, we intend to
      assess whether it is possible to lower the dose of apixaban (2.5 mg bid) after completing at
      least 6 months of anticoagulant treatment in a specific population of patients with cancer
      associated thrombosis (CAT) requiring extended anticoagulant treatment and with significant
      life expectancy. There are 2 conditions to be met : demonstrate the non-inferiority of the
      2.5 mg bid regimen on the efficacy endpoint and then demonstrate the superiority of the 2.5
      mg bid regimen as compared to the 5 mg bid on the safety endpoint.

      It is a multicenter, international, prospective, randomized, parallel-group, double-blind
      non-inferiority trial with blinded adjudication of outcome events (approximately 160 centers
      in approximately 10 countries (France, Italy, Spain, Belgium, Greece, Netherlands, UK,
      Switzerland, Poland, Austria), with a number of expected inclusions of 11 patients per site.

      Subjects should be randomized within 7 days after the last dose of their initial 6-month
      treatment, defined as the treatment ongoing after completing at least 6 months of
      anticoagulant treatment from the beginning of the anticoagulant treatment for the index
      event. This treatment may be low-molecular weight heparin (LMWH), direct oral anticoagulant
      (DOAC) or vitamin K antagonist (VKA). If a VKA was used as standard anticoagulant therapy,
      then an INR must be documented as 2 or less before randomization. Every attempt should be
      made to randomize subjects as soon as possible after the initial treatment has been
      discontinued.

      Subjects will be stratified based on the cancer site and the type of disease treated (PE
      with/without DVT or DVT alone). If a subject had both symptomatic DVT and symptomatic PE, the
      subject will be stratified as having symptomatic PE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of an an adjudicated composite endpoint</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>The incidence of an adjudicated composite of recurrent symptomatic VTE (proximal and/or distal DVT and/or symptomatic PE and/or upper limb or central venous catheter thrombosis or incidental VTE (proximal DVT or PE), or death due to PE during the treatment period.
Incidental VTE is defined as proximal DVT or PE detected by imaging incidentally when a patient undergoes imaging studies as standard of care for the management of the malignancy or other reasons but not for a VTE suspicion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adjudicated major and clinically relevant non-major bleeding</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>The definition of major bleeding described is adapted from the International Society on Thrombosis and Hemostasis (ISTH) definition (Schulman JTH 2005).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent symptomatic VTE</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>Recurrent VTE objectively confirmed after clinical suspicion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTE related-death</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>VTE related-death: PE based on objective diagnostic testing, autopsy, or sudden death; i.e. death occurring within one hour of the onset of new symptoms which cannot be attributed to a documented cause (unexplained death) and for which PE/DVT cannot be ruled out as the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>All deaths will be adjudicated by the ICAC and classified as either VTE-related, cancer death (including all deaths due to the underlying cancer), bleeding-related or others, including all deaths due to a clearly documented other cause, such as respiratory failure (e.g., terminal emphysema), infections/sepsis etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated major bleeding.</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>The definition of major bleeding described is adapted from the International Society on Thrombosis and Hemostasis (ISTH) definition (Schulman 2005) and includes
Acute clinically overt bleeding with one or more of the following:
A decrease in hemoglobin (Hgb) of 2 g/dL or more
A transfusion of 2 or more units of packed red blood cells
Symptomatic bleeding that occurs in at least one of the following critical sites:
Intracranial
Intraspinal
Intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed)
Pericardial
Intra-articular
Intramuscular with compartment syndrome
Retroperitoneal
Bleeding that is fatal: bleeding event that the independent adjudication committee determines is the primary cause of death or contributes directly to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated composite of recurrent symptomatic VTE, VTE related-death, all-cause death, adjudicated major bleeding.</measure>
    <time_frame>During the treatment period (12 months)</time_frame>
    <description>Adjudicated composite of recurrent symptomatic VTE, VTE related-death, all-cause death, adjudicated major bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1722</enrollment>
  <condition>Cancer-associated Thrombosis</condition>
  <arm_group>
    <arm_group_label>Apixaban film coated tablets 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban film coated tablets 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 MG</intervention_name>
    <description>Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).</description>
    <arm_group_label>Apixaban film coated tablets 2.5 mg</arm_group_label>
    <arm_group_label>Apixaban film coated tablets 5 mg</arm_group_label>
    <other_name>Apixaban 2.5 MG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Minimum Age: 18 Years

        Maximum Age:

        Sex: All Gender Based: No Accepts Healthy Volunteers: No

        Criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Any cancer diagnosed histologically (other than basal-cell or squamous-cell carcinoma
             of the skin, primary brain tumor or intra-cerebral metastasis)

          -  Active cancer defined as the presence of measurable disease or ongoing (or planned)
             chemotherapy, radiotherapy, hormonotherapy, targeted therapy, immunotherapy at
             inclusion

          -  Objectively documented index event : Symptomatic or incidental proximal lower-limb,
             iliac, inferior vena cava DVT or symptomatic or incidental pulmonary embolism in a
             segmental or larger pulmonary artery or incidental PE in a segmental or larger
             pulmonary artery

               1. Proximal DVT is defined as DVT that involves at least the popliteal vein or a
                  more proximal vein, demonstrated by imaging with compression ultrasound (CUS),
                  including grey-scale or color-coded Doppler, or ascending contrast venography or
                  contrast enhanced computed tomography or magnetic resonance imaging

               2. PE has to be demonstrated by imaging as follows:

                    -  an intraluminal filling defect in segmental or more proximal branches on
                       contrast enhanced chest computed tomography or on computed tomography
                       pulmonary angiography; or

                    -  an intraluminal filling defect or a sudden cutoff of vessels more than 2.5
                       mm in diameter on the pulmonary angiogram; or

                    -  a perfusion defect of at least 75% of a segment with a local normal
                       ventilation result (high-probability) on ventilation/perfusion lung scan
                       (VPLS)

               3. Incidental VTE is defined as proximal DVT or PE detected by imaging incidentally
                  when a patient undergoes imaging studies as standard of care for the management
                  of his or her malignancy or other reasons but not for a VTE suspicion(e.g. cancer
                  diagnosis or staging).

          -  Completed at least 6 months of anticoagulant therapy at therapeutic dosage (whatever
             the drug and the dosing),or completed assigned a clinical trial study treatment, for
             the treatment of the index event and patient still receiving anticoagulant treatment 6
             months after occurrence of the VTE index

          -  No objectively documented symptomatic recurrence of VTE between the index event and
             randomization.

          -  Anticipated duration of anticoagulant treatment of at least 12 months at the time of
             randomization

          -  Patient affiliated to social security for French centers.

        Exclusion Criteria:

          -  WOCBP who are unwilling or unable to use an acceptable method of birth control [such
             as oral contraceptives, other hormonal contraceptives (vaginal products, skin patches,
             or implanted or injectable products), or mechanical products such as an intrauterine
             device or barrier methods (condoms)] to avoid pregnancy for the entire study

          -  Women who are pregnant or breastfeeding

          -  Women with a positive pregnancy test on enrollment or prior to investigational product
             administration

          -  Isolated sub-segmental (incidental or symptomatic) PE without associated DVT

          -  Isolated distal DVT of the legs

          -  Isolated upper-extremity DVT or superior vena cava thrombosis

          -  Isolated visceral thrombosis

          -  Isolated catheter thrombosis

          -  Objectively documented symptomatic recurrence of VTE after the index event under
             anticoagulant treatment

          -  VTE during anticoagulant treatment given at therapeutic dosage

          -  Subjects with indications for long-term treatment with a VKA, such as:

          -  Mechanical heart valve

          -  Antiphospholipid syndrome

          -  Subjects with indication for long-term anticoagulation with a VKA or a DOAC at
             therapeutic dosage

          -  Conditions increasing the risk of serious bleeding

               1. intracranial or intraocular bleeding within the 6 months

               2. major surgery within 2 weeks prior to randomization

               3. overt major bleeding at time of randomization

          -  Life expectancy &lt; 12 months

          -  Eastern Cooperative Oncology Group (ECOG) level 3 or 4

          -  Bacterial endocarditis

          -  Uncontrolled hypertension: systolic blood pressure &gt;180 mm Hg or diastolic blood
             pressure &gt;110 mm Hg

          -  Platelet count &lt; 75,000/mm3

          -  Hemoglobin &lt; 8g /dl

          -  Creatinine clearance &lt; 30 ml /min based on the Cockcroft Gault equation

          -  Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine
             aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher
             the upper limit of the normal range

          -  Subjects requiring acetylsalicylic acid &gt;165 mg/day at randomization or thienopyridine
             therapy (clopidogrel, prasugrel, or ticagrelor).

          -  Subjects requiring dual anti-platelet therapy (such as acetylsalicylic acid plus
             clopidogrel or acetylsalicylic acid plus ticlopidine) at randomization. Subjects who
             transition from dual antiplatelet therapy to monotherapy prior to randomization will
             be eligible for the trial.

          -  Concomitant use of strong inhibitors of both cytochrome P-450 3A4 and P Glycoprotein
             (e.g., human immunodeficiency virus protease inhibitors or systemic ketoconazole) or
             strong inducers of both cytochrome P450 3A4 and P Glycoprotein (e.g.,rifampicin,
             carbamazepine, or phenytoin).

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (eg, infectious disease) illness

          -  Hypersensitivity to apixaban

          -  Subjects participating in another pharmaco therapeutic program with an experimental
             therapy that is known to affect the coagulation system

          -  Under 18 years old

          -  Patients under legal protection (guardianship).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Meyer, Pr</last_name>
    <role>Study Director</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Mahé, Pr</last_name>
    <phone>+33 (0)1 47 60 64 90</phone>
    <email>isabelle.mahe@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofiane DJAILEB, Mr</last_name>
    <phone>+33(0)1 57 27 84 58</phone>
    <email>sofiane.djaileb@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Louis Mourier - APHP</name>
      <address>
        <city>Colombes</city>
        <state>Ile De France</state>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Mahe, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. D'Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Antoinette Sevestre, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu D'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Henni, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÔPITAL PRIVÉ ARRAS LES BONNETTES - Espace Artois Santé</name>
      <address>
        <city>Arras</city>
        <zip>62012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Debourdeau, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa Kalbacher, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital AVICENNE - APHP</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Lejeune, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Krakowski, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Clermont Tonnerre</name>
      <address>
        <city>Brest</city>
        <zip>29240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chru Brest - Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chru Brest- Hopital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Couturaud, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle Levy, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien Laneelle, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Du Parc</name>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34171</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ch Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anaise Blouet, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hia Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Doutrelon, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot Schmidt, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital BEAUJON - APHP</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital HENRI MONDOR - APHP</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Assaf, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DIJON BOURGOGNE - Hôpital François Mitterrand</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Falvo, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Brebion, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Tequi, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabrielle Sarlon Bertoli, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint- Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Quere, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H. Des Pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre D Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Spaeth, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE Nantes - Site Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Connault, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emile Ferrari, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irène Kriegel, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grigoris GEROTGIAFAS, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital PITIE SALPETRIERE - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Villemain, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital COCHIN - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Coriat, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital GEORGES POMPIDOU - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Meyer, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon - Aphp</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grigorios Gerotziafas, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie BONHOMME, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Grange, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51057</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Jovenin, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Anti-Cancereux E. Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bettina Boutruche, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ygal Benhamou, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.I Poissy-Saint Germain</name>
      <address>
        <city>Saint Germain En Laye</city>
        <zip>78105</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asmahane Tellier, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Okba-Ibn-Nafaa Bensaoula, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Bertoletti, PUPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de l' Estrée</name>
      <address>
        <city>Stains</city>
        <zip>93240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Trager, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis-Marie Dourthe, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi de Toulon La Seyne</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Elias, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iuct Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Eche Gass, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Andre Mignot</name>
      <address>
        <city>Versailles</city>
        <zip>78000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Mayeur, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse - APHP</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayhan Ulusakarya, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mir Olivier, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>VTE</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

